Cefazolin Is Associated With a Lower Periprosthetic Joint Infection Risk than Alternative Antibiotic Regimens Following Total Hip Arthroplasty.

BACKGROUND

There have been conflicting reports on the risk of periprosthetic joint infection (PJI) with the use of alternative antibiotics to cefazolin following arthroplasty. We leveraged recent data from a nationally representative multipayer dataset to investigate this question.

METHODS

We queried a health care dataset from 2016 to 2022 to identify primary total hip arthroplasties (THAs) using Current Procedural Terminology and International Classification of Disease (ICD)-Procedure Coding System codes (27130, 0SR90xx, 0SRB0xx) with a corresponding osteoarthritis diagnosis (ICD-Clinical Modification: M16). Patient demographics, characteristics, and outcomes were extracted from existing dataset variables. The PJIs were defined using ICD-10 diagnosis codes from the Centers for Medicare and Medicaid Services' procedure-specific complication measure within 90 days of surgery. We compared PJI between patients receiving cefazolin antibiotic prophylaxis and patients who received an alternative antibiotic or cefazolin plus another antibiotic. The association between cefazolin use and PJI was evaluated using multinomial logistic regression. This study included 289,369 primary THA patients from 2016 to 2022. There were 25,164 patients (8.7%) who received a non-cefazolin antibiotic, 200,367 (69.2%) received cefazolin only, and 63,838 (22.1%) received cefazolin plus an alternative antibiotic.

RESULTS

In univariate analysis, there was a significant difference in the rate of 90-day PJI between the non-cefazolin group, cefazolin only, and cefazolin plus other antibiotic group (0.9, 0.5, and 0.5%, respectively, P < 0.001). In a logistic regression analysis that adjusted for age, sex, payer, race, ethnicity, and Elixhauser Comorbidity Index, the use of cefazolin only and cefazolin plus other antibiotic were associated with reduced risk of 90-day PJI (odds ratio 0.62, 95% confidence interval [0.53 to 0.72], P < 0.001) and (odds ratio 0.64, 95% confidence interval [0.54 to 0.76], P < 0.001).

CONCLUSIONS

In this nationally representative multipayer study using recent data, patients who received antibiotic prophylaxis with cefazolin had lower 90-day rates of PJI compared to those receiving alternative antibiotics during primary THA.